At what enterprise value was LABORATOIRES ANIOS acquired in 2017?

During the acquisition of LABORATOIRES ANIOS by ECOLAB in 2017, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 500M - 1.5b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of LABORATOIRES ANIOS when it was acquired by ECOLAB?

The estimated EV/EBITDA multiple for LABORATOIRES ANIOS is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was LABORATOIRES ANIOS acquired by ECOLAB?

LABORATOIRES ANIOS was acquired by ECOLAB in 2017.

What was the revenue of LABORATOIRES ANIOS at the time of the deal?

The revenue of LABORATOIRES ANIOS at the time of the deal is estimated to be in the range of 150M - 250M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of LABORATOIRES ANIOS during the acquisition?

LABORATOIRES ANIOS's EBITDA is estimated to be in the range of 50M - 100M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the LABORATOIRES ANIOS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the LABORATOIRES ANIOS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.ardian.com/sites/default/files/2020-04/CP-Cession-Anios-20170201-FR.pdf

← DATABASE

Home Database Healthcare & PharmaLABORATOIRES ANIOS

02/2017

LABORATOIRES ANIOS acquired by ECOLAB

FRANCE Life Sciences / Medical Devices / Medical Consumables EV 500M - 1.5b EUR

Context

Ecolab has completed the acquisition of 100% of Laboratoires Anios from Ardian and the Letartre family. This transaction represents a definitive exit for the private equity firm Ardian, which had supported the founding family in a 2013 LBO following a previous ownership cycle by Air Liquide. The strategic rationale for Ecolab is to establish a dominant foothold in the European hospital disinfection market, a segment where it was previously underrepresented. For Anios, the merger provides a global springboard, particularly to accelerate its expansion into the Chinese market. Over the three years of Ardian’s ownership, Anios achieved a 25% increase in revenue and a 55% jump in EBITDA, driven by a series of five strategic "bolt-on" acquisitions.

It is worth noting that the fund Ardian took control of Laboratoires Anios through an LBO in 2013.

LABORATOIRES ANIOS, which reported an EBITDA margin of LOGIN in 2016, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded by the Letartre family and based in Lille, Laboratoires Anios is a European leader in the hygiene and disinfection sector for hospitals, clinics, and industrial environments. The company provides holistic solutions for medical device disinfection, including endoscope washer-disinfectors, as well as products for the food and professional cleaning industries. Its business model integrates high-intensity R&D with specialized chemical manufacturing across international sites.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2016

2015

Other operations with LABORATOIRES ANIOS

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
10/2013	ARDIAN	LABORATOIRES ANIOS	FRANCE	Life Sciences	Air Liquide has entered into exclusive negotiations to sell its 66% majority stake in Laboratoires Anios to a consortium comprised of Ardian and the founding Letartre brothers, Bertrand and Thierry. This transaction represents a strategic spin-off for Air Liquide, allowing the industrial gas giant to refocus its hygiene activities exclusively on its German subsidiary, Schülke & Mayr

REFERENCES

Valuation range: EV 500M - 1.5b EUR

Revenue range: 150M - 250M EUR

EBITDA range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of LABORATOIRES ANIOS by ECOLAB are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: laboratoires anios